Lead Inventor Clyde M. Ofner III, Ph.D Unmet Need A major challenge in cancer chemotherapy is the selective delivery of small molecule anti-cancer agents to cancer cells. Doxorubicin (DOX) is a potent antineoplastic agent that is effective against a wide range of solid tumors and lymphomas but it is also associated with an irreversible cardiomyopathy […]
A Drug Therapy Utilizing the Alpha4 / Beta2 Receptor Target for the Treatment of Obsessive-Compulsive
Tandem Cytotoxic Drug Delivery & p53-Status-Independent Apoptosis Promotion.
LICENSED: Orally administered phenylalanine ammonia lyase microcapsules for the management of phenylketonuria (PKU).
A cell-based method to determine surface heterogeneity on polystyrene used in tissue culture flasks and dishes; increasing reliability of outcome of cell assays and reducing necessity to repeat cell-based tests.
TechTransCo, LLC d/b/a L2C Partners (“L2C Partners”) is not a registered broker-dealer or a registered investment adviser. You understand that the business plans of the companies posted on this website are furnished for your personal, noncommercial, informational purposes only, and that the inclusion of any company’s business plan (a “Company Plan”) on this website does not constitute an offer to sell, or a recommendation to buy, sell, or hold, any security of that company. To the extent that any of the information contained in any Company Plan may be deemed to be an offer to sell securities or investment advice, such information is impersonal and not directed towards any specific person. You agree and acknowledge that you are responsible for your own investment decisions with respect to any security of a company whose Company Plan is posted on this website.
L2C Partners has not reviewed any Company Plan posted on this website, and does not represent or warrant that any such Company Plan is accurate, reliable, correct or complete. THE COMPANY PLANS ARE PROVIDED "AS IS," “WHERE IS” AND “WITH ALL FAULTS,” AND L2C PARTNERS MAKES NO WARRANTY WITH RESPECT TO ANY COMPANY PLAN OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF ACCURACY, COMPLETENESS, TIMELINESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND EXPRESSLY DISCLAIMS ALL SUCH WARRANTIES.
YOU AGREE AND ACKNOWLEDGE THAT NEITHER L2C PARTNERS NOR ITS AFFILIATES, MEMBERS, MANAGERS, OFFICERS, EMPLOYEES, BUSINESS PARTNERS, ADVISORS OR AGENTS (THE “L2C PARTIES”) SHALL HAVE ANY LIABILITY (JOINTLY OR SEVERALLY) TO YOU OR TO ANY OTHER PERSON FOR THE ACCURACY, RELIABILITY, CORRECTNESS OR COMPLETENESS OF ANY SUCH COMPANY PLAN, OR FOR ANY LOSSES, DAMAGES, EXPENSES, CLAIMS, OBLIGATIONS OR LIABILITIES, INCLUDING, WITHOUT LIMITATION, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS (COLLECTIVELY, THE “EXCLUDED DAMAGES”), ARISING FROM OR RELATED TO YOUR OR ANY OTHER PERSON’S USE OF OR RELIANCE ON THE CONTENT OF ANY COMPANY PLAN, WHETHER OR NOT CHARACTERIZED IN NEGLIGENCE, TORT, CONTRACT, OR OTHER THEORY OF LIABILITY, EVEN IF ANY OF THE L2C PARTIES HAVE BEEN ADVISED OF THE POSSIBILITY OF OR COULD HAVE FORESEEN ANY OF THE EXCLUDED DAMAGES. IF ANY PORTION OF THIS DISCLAIMER IS HELD TO BE UNENFORCEABLE, THEN THE L2C PARTIES' LIABILITY WILL BE LIMITED TO THE FULLEST POSSIBLE EXTENT PERMITTED BY APPLICABLE LAW.